TikTok is introducing a new feature called "Series" that allows users to create longer-form video content behind a paywall.
One Series can include up to 80 videos that are 20 minutes or less, and creators get to decide how much access to this content will cost their fans.
"Creators can select how much their Series should cost that best reflects the value of their exclusive content, which can be purchased for access via direct in-video links or through a creator’s profile," the company wrote in a blog post.
The company said the offering fits into a number of "monetization solutions" to make creators "feel valued and rewarded" as they produce content for the controversial platform.
"As we're in the early stages of Series, we'll continue to listen closely to our community for feedback," it wrote.
The announcement comes as Sen. Mark Warner, D-Va. champions a bill that could give the Commerce Secretary power to fully ban the Chinese-owned TikTok from the U.S.
Conditions have been mostly nice for travelers flying ahead of and on Christmas Day, but some naughty disruptions plagued those flying with Southwest Airlines again this year.
Gift cards make great stocking stuffers — just as long as you don't stuff them in a drawer and forget about them after the holidays.
Big Business This Week is a guided tour through the biggest market stories of the week, from winning stocks to brutal dips to the facts and forecasts generating buzz on Wall Street.
Bristol Myers Squibb agreed to buy schizophrenia drug maker Karuna Therapeutics in a $14 billion deal.
Supermarket chain Ralphs is facing a new lawsuit from the state of California.
Shake Shack is giving out free fried chicken sandwiches, bacon cheese fries and milkshakes nationwide.
The IRS is announcing a voluntary disclosure program.
Lionsgate announced its studio division is going to spin off in a merger with Screaming Eagle Acquisition Corp., which is a special purpose acquisition company.
A new report suggests that it's getting more difficult for an average American to afford a home.
The Food and Drug Administration warned consumers about a copycat version of the diabetes drug Ozempic.
